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See Article, pages 702–710Several non-hereditary liver diseases are associated
with mild hepatic iron overload such as viral hepatitis,
excessive alcohol consumption, non-alcoholic fatty liver
disease (NAFLD) or non-alcoholic steatohepatitis
(NASH) [1–7]. In fact, the term insulin resistance or dys-
metabolic iron overload syndrome was introduced to
describe the association of body iron overload and
NAFLD [8]. The contribution of HFE-mutations to the
development of iron overload in these diseases remains
debated [9,10] (NAFLD/NASH [8,11,12]) (HCV
[13–15]) (alcohol [16]), but is probably slight.
The underlying molecular mechanism centers on
dysregulation of the iron regulatory hormone hepcidin.
Hepcidin is primarily produced by hepatocytes, but there
is also evidence for production by macrophages [17] and
fat cells [18]. Hepcidin internalizes and subsequently
degrades the cellular iron exporter ferroportin, present
on the cell surface ofmacrophages and enterocytes, result-
ing in hypoferremia. Hepcidin is upregulated by inﬂam-
mation, by the presence of increased body iron levels
and inhibited by increased erythropoietic activity. These
respective regulatory pathways are thought to protect
the body from (i) extracellular proliferating pathogens,
(ii) the harmful eﬀects of iron overload and to (iii) ensure
that body iron availability matches iron needs.0168-8278/$34.00  2008 European Association for the Study of the Liver.
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of hepcidin underlies non-hereditary (or non-hemochro-
matotic or acquired) mild iron overloading hepatic dis-
eases (NHIOD). Hepcidin expression is aﬀected by the
upstream stimulatory factor 1 (USF1), a well established
susceptibility gene for familial combined hyperlipid-
emia, a complex disorder of lipid metabolism [19].
USF1 together with USF2 controls cis and trans regula-
tion of hepcidin expression [20]. Other circumstantial
evidence of a link between hepcidin, glucose and lipid
metabolism comes from hepcidin producing hepatic
adenomas in severe anemic type 1a glycogen storage
disease (GSD1a) patients [21], and hepcidin production
by fat cells [18]. Interestingly, many of the diseases that
are part of the metabolic syndrome have a disrupted
iron homeostasis [3,4] (e.g. diabetes [1,2,8], hypertension
[22] and elevated body mass index [23]). Thus, we are
only starting to discover the pleiotropic role of hepcidin.
Alcoholic and hepatic viral infections are themost typ-
ical examples of acquired mild forms of iron overload.
Liver biopsies in these disorders consistently show iron
deposits in hepatocytes and Kupﬀer cells [5,24]. Elevated
liver iron deposits are also commonly observed in
NAFLD [5,24].
Iron can induce oxidative stress, which can cause tis-
sue injury. Indeed, hepatic iron deposits have been asso-
ciated with more advanced forms of NHIOD, including
liver ﬁbrosis, cirrhosis and hepatocellular cancer in some
reports (NAFLD/NASH [9,11,25,26] , HCV [27–29] ,
alcohol [30,31]), but this was not conﬁrmed in others
(NAFLD/NASH [12,32,33] , HCV [16,30]).
In NAFLD, there is increased urinary hepcidin
excretion [34] and elevated liver hepcidin expression
[35] but hepcidin levels are relatively low for the levelPublished by Elsevier B.V. All rights reserved.
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sensing.
In this issue of the Journal of Hepatology, Fujita et al.
[36] conﬁrm that in chronic hepatitisCvirus (HCV), hepa-
tic hepcidin expression is inadequate for the body iron
stores, but can be restored upon viral eradication. In addi-
tion, they found that hepatic hepcidin expression reﬂects
circulating hepcidin levels. This ﬁnding suggests that
serum hepcidin measurements might become a proxy
parameter for hepatic hepcidin and aid in the manage-
ment of patients with acquired forms of mild hepatic iron
overload such as in HCV.
1. Hepcidin peptide
Human hepcidin is mainly produced by hepatocytes
as an 84 amino-acid (aa) pre-prohepcidin [37]. Subse-
quent posttranslational processing results in the biolog-
ically active 25 aa form (hepcidin-25, molecular mass is
2789 Da) that is secreted in the plasma. Additional
amino-acid degradation results in the production of
two smaller isoforms (hepcidin-20 and -22) [38,39], that
have unknown biological signiﬁcance.
2. Hepcidin assay
Progress in this ﬁeld has been hampered by the diﬃ-
culties many researchers face by measuring hepcidin.
Until recently, only few tools were available to measure
hepcidin. Largely because antibodies are hard to raise.
Hepcidin has a small and compact structure and anti-
genic epitopes are scarce. In addition, hepcidin is con-
served among a wide range of species which
complicates the induction of antibodies in hosts such
as rabbit. As a consequence, immunochemical methods
based on speciﬁc anti-hepcidin antibodies are largely
unavailable. Lastly, quantitation of hepcidin is compli-
cated by its tendency to aggregate [40] and stick to lab-
oratory plastics, necessitating implementation of robust
laboratory procedures.
Currently, many studies use the serum-based com-
mercial immunoassay that measures the hepcidin pre-
cursor prohepcidin rather than the bioactive peptide.
The relevance of these data is controversial because pro-
hepcidin levels fail to correlate with urinary and serum
hepcidin [41,42]. Furthermore, when measured in
healthy controls, serum prohepcidin levels are around
40–50 times higher than those observed for bioactive
hepcidin (180 ng/ml versus 4 ng/ml) (unpublished
observations). This suggests that prohepcidin and hepci-
din have diﬀerent biological proﬁles [41–44].
Ganz and Nemeth et al. have developed an immuno-
dotblot assay using non-commercially available anti-
bodies for the semi-quantitative measurement of the
sum of all urinary hepcidin isoforms [45]. The results
of studies that employ this method have greatlyimproved our understanding of the regulation of hepci-
din in patients with distorted iron homeostasis [46].
More recently, new assays for the various hepcidin
isoforms: hepcidin-25, -22 and -20 have been developed
on a platform of novel technologies such as surface
enhanced laser desorption/ionization time-of-ﬂight mass
spectrometry (SELDI-TOF MS) and liquid chromatog-
raphy tandem MS (LC/MS–MS) [38,47–49]. With the
use of internal standards these MS techniques enable
reliable quantitative hepcidin analysis in urine and
serum (Fig. 1) [50,51]. In fact, MS optimally uses an
internal standard to correct for extraction, variable
ionization and suppression of the analyte. Internal stan-
dards are spiked to the clinical samples and co-analysed.
The ratio between the synthetic internal standard and
endogenous peptide is determined by MS, allowing cal-
culation of the absolute amount of hepcidin.
In the current issue Fujita et al. exploit SELDI-TOF
MS to (semi)quantify circulating hepcidin-25 levels
[36,47]. This method shares the drawback of most cur-
rently available hepcidin analysis since it lacks the use
of an internal standard. This precludes value assign-
ment, necessitating expression in arbitrary units, and
resulting in somewhat imprecise measurements. Never-
theless, their results provide important proof of princi-
ple insights in biologically relevant circulating hepcidin
levels in HCV before and after treatment.
3. Clinical utility of the hepcidin assay
Before measurement of hepcidin in urine and serum
can be introduced into routine clinical practice, several
issues need to be addressed. This starts with establish-
ment of reference values among a wide variation of con-
trols, and the assessment of a diurnal variation or
ﬂuctuation in relationship to meals.
Proof of principle ﬁndings of a circadian (either
intrinsic or diet related) variation with generally lower
values in the fasted morning samples than in the after-
noon [38], may necessitate standardized sampling in
the morning after an overnight fast (as was nicely done
by Fujita et al.).
Another relevant question is whether urine is a reli-
able alternative for serum to assess biologically relevant
hepcidin levels. Urine hepcidin levels correlate with hep-
cidin expression in liver biopsies [52], but discrepancies
have been reported [34]. Urine levels also correspond
to circulating levels [38] and nicely ﬁt in the concept of
hepcidin as the iron regulatory peptide [46,53]. Still,
we caution against the uncritical use of urine concentra-
tions as a universal surrogate for circulating levels since
urinary secretion of hepcidin will depend on glomerular
ﬁltration and tubular re-absorption. In addition, hepci-
din mRNA has been detected in the kidney, which sug-
gests the potential for local production and release into
the urine [54].
Fig. 1. Proposed mechanism for iron loading in non-hemochromatotic iron overload disease. Increased hepatic iron overload is associated with the
reactive oxygen species (ROS) mediated reduction of hepcidin expression, an increase in duodenal ferroportin levels and a corresponding increase in iron
absorption and of serum iron levels [64–67]. Alcohol and hepatitis C virus-induced ROS down regulate liver hepcidin transcripts by inhibiting the DNA-
binding activity of the transcription factor CCAAT/enhancer binding protein alpha (C/EBPa) [64,65]. IS, internal standard; hepc 25, 22 and 20, hepcidin
isoforms of 25, 22 and 20 amino-acids, respectively; Fe, iron.
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Increased hepatic, urinary and serum hepcidin levels
are found in obesity [18], dysmetabolic iron overload
syndrome [34,35] and the metabolic syndrome (our
unpublished observations). This (moderate) increase is
likely due to a combination of (i) (low grade) inﬂam-
mation and cytokine induced hepcidin production in
hepatocytes [46,53,55] and (ii) hepcidin production by
fat cells [18] especially in severe obese. At ﬁrst sight,
these increased absolute levels contrast to the mild
parenchymal overload as observed in NHIOD, because
hepcidin inactivates ferroportin which, in theory,
should decrease iron uptake by the intestine. However,
the precise functional eﬀect of circulating hepcidin lev-
els on iron release of various cell-types, among them
enterocytes, is unknown yet. There is some evidence
of hepcidin-independent regulation of iron absorption
(reviewed in [56]). Other data suggest that hepcidin
eﬀects might be cell speciﬁc [57]. It is therefore
plausible to postulate that in obesity related NHIOD
(and possibly also in HCV and alcoholic liver disease)
enterocytes are relatively resistant to circulating
hepcidin, resulting in a relatively high intestinal iron
absorption for the circulating hepcidin levels, while
macrophages are more sensitive, leading to RES iron
sequestration.5. Hepcidin/ferritin ratio and common mixed pattern of
iron deposits
Key in the report of Fujita et al. is their novel ﬁndings
on reduced liver iron sensing in chronic HCV and espe-
cially its reversibility upon viral eradication. Similar to
earlier studies in HH [51,58], they assessed inadequate
iron sensing by calculation of the hepcidin/ferritin ratio.
In our view the suitability of this ratio as a measure of
inadequately increased duodenal iron uptake in NHIOD
is uncertain. There might be unknown molecular players
that regulate iron stores but are not taken into account.
The pattern of iron deposits in NHIOD are typically
mixed: i.e. found in both Kupﬀer cells and the hepato-
cytes [5,24,59]. Regulation of hepatocyte hepcidin
expression through the iron-sensing pathway appears
to be independent of Kupﬀer cells [60,61]. These obser-
vations suggest that the hepcidin/ferritin ratio is only
suitable as a measure to assess the adequacy of hepcidin
regulation by the iron stores of parenchymal cells. This
would implicate that a low ratio primarily inadequately
predicts increased intestinal iron uptake when ferritin in
the denominator reﬂects the iron levels in these paren-
chymal cells, such as occurs in various forms of HH.
Hence, in NHIOD the decrease in hepcidin/ferritin ratio
is likely to overestimate the reduction of iron sensing of
parenchymal iron levels and the subsequent inadequate
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to explain the observed Kupﬀer cell iron loading. It is
therefore tempting to speculate that in HCV and other
NHIOD local RES produced small amounts of inﬂam-
matory cytokines and hepcidin are involved in RES iron
sequestration by decreasing ferroportin activity [62,63].
Clearly, more work is warranted to unravel the biolog-
ical mechanism explaining the distorted iron homeostasis
in these patients to assess the suitability of the hepcidin/
ferritin ratio or its alternative log transformations as a
marker for inadequately elevated intestinal iron uptake.6. Hepcidin in the management of patients with NHIOD
By assessing serum hepcidin levels in HCV Fujita
et al. [36] corroborate previous ﬁndings on a decreased
liver iron sensitivity as a uniform mechanism underlying
mild hepatic iron overload. Down regulation of liver
hepcidin expression by increased hepatic reactive oxygen
species (ROS) by inhibition of the DNA-binding of C/
EBPa might be an important causal factor in this appar-
ent decrease in hepatocyte iron sensing (Fig. 1).
Based on this role of hepcidin in NHIOD in general
and chronic HCV in particular we propose that hepcidin
may contribute to predicting and monitoring of iron
overload in these patients. Relatively low hepcidin levels
may indicate an increased risk of iron overload and nor-
malization possibly points to the successful HCV eradi-
cation by antiviral regimes. Normalization of hepcidin
levels by iron reduction (by e.g. dietary restriction, phle-
botomy, iron chelation), antioxidants or hepcidin induc-
ers or supplements, may perhaps be suitable as add-on
treatment options for patients with NHIOD to improve
the detrimental eﬀects of iron on liver function. It is con-
ceivable that in the case of HCV, hepcidin elevating
therapies lead to an improved response to antiviral
treatment. However, before we can translate these newly
acquired insights into clinical practice, additional studies
will be needed to further unravel critical cellular iron
transporters involved in iron homeostasis in NHIOD.
Finally, if hepcidin proves to be a useful marker in
the management of non-hemochromatotic iron overload
reliable, accessible, high throughput, aﬀordable and
reproducible methods will be needed to facilitate the
measurements that hepatologists need.Acknowledgments
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